Belpointe Asset Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.23M Buy
15,682
+594
+4% +$40.5K 0.04% 429
2026
Q1
$975K Buy
15,088
+7,123
+89% +$502K 0.04% 461
2025
Q4
$536K Buy
7,965
+3,677
+86% +$247K 0.02% 631
2025
Q3
$314K Buy
+4,288
New +$285K 0.01% 780
2024
Q4
Sell
-4,403
Closed -$252K 904
2024
Q3
$252K Buy
4,403
+526
+14% +$30.2K 0.02% 723
2024
Q2
$203K Buy
+3,877
New +$170K 0.01% 729
2023
Q2
Sell
-1,238
Closed -$47.3K 1721
2023
Q1
$47.3K Buy
1,238
+366
+42% +$17.2K ﹤0.01% 1736
2022
Q4
$49.6K Buy
+872
New +$44.6K ﹤0.01% 1619

Other funds holding HALO

Belpointe Asset Management's HALO Position: Q2 2026 in Review

Belpointe Asset Management increased its Halozyme (HALO) stake by 3.9% in Q2 2026, buying an estimated $40.5K and bringing the position to 15,682 shares worth $1.23M. The position accounts for 0.04% of the portfolio, ranked #429.

Belpointe Asset Management first reported a position in HALO in Q4 2022 and has held it in 8 quarters since. 672 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Belpointe Asset Management held 15,682 shares of Halozyme worth $1.23M as of Q2 2026.
  • Belpointe Asset Management bought 594 Halozyme shares in Q2 2026, an estimated $40.5K.
  • Halozyme made up 0.04% of Belpointe Asset Management's portfolio in Q2 2026, its #429 holding.
  • Belpointe Asset Management first reported a position in Halozyme in Q4 2022 and has held it in 8 quarters since.
  • 672 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.